Connecticut Clinical Trials Report — July 2026

Connecticut residents considering a clinical trial should check eligibility soon: 50 recruiting studies are projected to close within the next 90 days. Nine of these accept healthy volunteers, creating a particularly narrow window for people who do not have the condition being studied. Enrollment dates can change, and screening may take time, so prospective participants should contact study teams promptly.

The state currently has 1,240 recruiting trials across 49 cities and 592 research sites. Fourteen new studies opened in July, down from 18 in June and 23 in May. The six-month pattern shows a steady slowdown in new openings, from 34 in February to 14 this month, with only 4 additional openings currently recorded for August.

Closing-soon studies create immediate opportunities

People with breast cancer, alcohol-related conditions, ADHD, bipolar I disorder, or certain blood cancers may find the most time-sensitive options. The closing-soon list includes two breast cancer trials and multiple studies involving alcohol use, alcohol-related disorders, or alcohol use disorder. Acute myeloid leukemia, including AML with mutated NPM1, also appears more than once.

• Breast cancer — 2 closing-soon trials
• Alcohol use, alcohol-related disorders, and alcohol use disorder — 6 combined listings
• AML, including AML with mutated NPM1 — 2
• ADHD, advanced solid tumor, and bipolar I disorder — 1 each

Healthy volunteers should not assume that a closing study is limited to patients. Nine of the 50 studies nearing closure accept healthy participants, while 148 healthy-volunteer trials are recruiting statewide overall. Those considering compensated research, surveys, behavioral studies, or other non-treatment opportunities should compare requirements carefully, including age, sex, travel, and visit schedules.

July brings a smaller but varied group of new studies

Fourteen trials opened in July, spanning alcohol use disorder, AML, cancer, diabetes, type 2 diabetes, grief, irritability, facial conditions, gastric or gastroesophageal junction adenocarcinoma, and research involving healthy adults. Drug studies led the month with 8 openings. Behavioral studies accounted for 4, while one device study, one diagnostic test, and one study classified as other completed the mix.

• Alcohol use disorder, AML, cancer, diabetes, type 2 diabetes, face, gastric or gastroesophageal junction adenocarcinoma, grief, irritability, and healthy adults — 1 new trial each
• Drug trials — 8
• Behavioral trials — 4
• Device, diagnostic-test, and other studies — 1 each

Yale University sponsored 7 of the new studies, making it the dominant source of July openings. Industry sponsors accounted for 5 trials, federal research for 1, and other sponsor classifications for 8. Named sponsors include Amgen, Jazz Pharmaceuticals, Pfizer, Akeso, UConn Health, the VA Office of Research and Development, and TScan Therapeutics.

Major Phase 2 and Phase 3 studies at Connecticut sites

Several new trials stand out because of their phase, enrollment size, or sponsor. Amgen’s Phase 3 extension study of maridebart cafraglutide is one of the largest new opportunities. NCT07684235 plans to enroll 3,200 people with obesity or overweight and will assess long-term efficacy, safety, and tolerability. The study extends an earlier trial, so people who participated in the prior research may want to ask whether they can qualify.

• NCT07684235 — Amgen’s Phase 3 extension study of maridebart cafraglutide for people with obesity or overweight; planned enrollment of 3,200.
• NCT07700979 — Akeso’s Phase 3 study of cadonilimab plus chemotherapy versus chemotherapy with or without nivolumab for previously untreated, unresectable, or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma; planned enrollment of 900.
• NCT07702578 — TScan Therapeutics’ Phase 3 study of genetically engineered donor T cells after allogeneic stem cell transplantation; planned enrollment of 310.
• NCT07723963 — Jazz Pharmaceuticals’ Phase 2/Phase 3 study evaluating JZP926 for juvenile myoclonic epilepsy; planned enrollment of 260.
• NCT07730294 — Yale’s Phase 2 study of intranasal oxytocin for pain relief and recovery after pituitary surgery; planned enrollment of 75.

Yale also opened NCT07689864, a large liquid-biopsy repository study with planned enrollment of 2,500. The Unified Network for Integrated Fluid Collection at Yale will prospectively collect blood samples, dried blood spots, and optional archival tissue from Yale Cancer Center patients across tumor types for current and future research. Unlike a conventional treatment trial, this study is focused on building a research resource.

For adults with type 2 diabetes, Yale’s NCT07689877 GUIDE study will evaluate an integrated digital-health intervention, with and without healthcare-provider engagement, to improve glycemic control and diabetes-related outcomes. Another behavioral opportunity is the VA Office of Research and Development’s Phase 2 NCT07738445, a retreat-based program for violence-exposed women Veterans. It will assess feasibility, acceptability, and preliminary efficacy in a specialized population facing elevated suicide risk and barriers to Veterans Health Administration care.

New Haven dominates, with additional access around the state

New Haven was the clear center of July activity, accounting for 9 of the 14 new trials. Hartford, Milford, Farmington, North Haven, Waterbury, and West Haven each added 1 new study.

• New Haven — 9 new trials
• Hartford, Milford, Farmington, North Haven, Waterbury, and West Haven — 1 each

This pattern shows a strong concentration around Yale and the New Haven research network, while also providing openings in Hartford County and several other communities. Because the state has 592 research sites across 49 cities, patients should search beyond the city closest to home. A trial may have a convenient Connecticut site even when its primary sponsor is based elsewhere, but some studies require frequent visits or specialized procedures.

Who should act now?

Healthy adults have two new-trial opportunities among July’s openings, and nine healthy-volunteer studies are nearing closure. Overall, 148 healthy-volunteer trials are recruiting statewide. People without a diagnosed condition should review these listings now, especially if they can travel to New Haven or meet narrow age, sex, or scheduling requirements.

Children are included in 1 new trial, and 1 July study is female-only. No new trial is male-only. Older adults are included in 11 new studies, making age-appropriate research one of the broader eligibility pathways this month. People with AML, breast cancer, alcohol-use concerns, diabetes, epilepsy, obesity, or advanced gastrointestinal cancers should also investigate quickly because both new and closing-soon studies address these conditions.

Connecticut’s trial pipeline is likely to remain competitive through late summer: openings have declined month by month, while dozens of existing studies are approaching their projected enrollment deadlines. For patients and healthy volunteers who find a promising match, early contact with the research site may be the difference between completing screening and missing the enrollment window.